Clinical Trial Detail

NCT ID NCT02563548
Title Phase 1b Open-Label Study of PEGPH20 With Pembrolizumab
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements No
Sponsors Halozyme Therapeutics
Indications

gastric adenocarcinoma

lung non-small cell carcinoma

Therapies

PEGPH20 + Pembrolizumab

Age Groups: adult senior

No variant requirements are available.